Abstract
Drug-induced pemphigoid (DIBP) and drug-induced linear IgA bullous dermatosis (DILAD) can be difficult to differentiate from idiopathic bullous pemphigoid (BP) or mucous membrane pemphigoid (MMP), respectively linear IgA disease (LAD). Possible absence or only minor differences in clinical, histopathologic and immunopathologic features complicate the recognition. However, differentiation can be of major importance because of a different approach, prognosis, and treatment. Diagnosis is mainly based on a clear time-relation between start of the suspected drug(s) and onset of the lesions, but can be complicated by polypharmacy and comorbidity, especially in the elderly. After withdrawal of the culprit drug, both DIBP and DILAD tend to be self-limiting. With the introduction of immune checkpoint inhibitors in treatment of malignancies, pemphigoid variants may present as an immune-related adverse event, leading to a dilemma in treatment choices.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lo Schiavo A, Ruocco E, Brancaccio G, Caccavale S, Ruocco V, Wolf R. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies. Clin Dermatol. 2013;31(4):391–9.
Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol. 1998;16(3):379–87.
Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28(9):1133–40.
Bastuji-Garin S, Joly P, Picard-Dahan C, Bernard P, Vaillant L, Pauwels C, et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol. 1996;132(3):272–6.
Verheyden MJ, Bilgic A, Murrell DF. A systematic review of drug-associated bullous pemphigoid. Acta Derm Venereol. 2020;100:adv00224.
Yamagami J, Nakamura Y, Nagao K, Funakoshi T, Takahashi H, Tanikawa A, et al. Vancomycin mediates IgA autoreactivity in drug-induced linear IgA bullous dermatosis. J Invest Dermatol. 2018;138:1473–80.
Lings K, Bygum A. Linear IgA bullous dermatosis: a retrospective study of 23 patients in Denmark. Acta Derm Venereol. 2015;95:466–71.
Lammer J, Hein R, Roenneberg S, Biedermann T, Volz T. Drug-induced linear IgA bullous dermatosis: a case report and review of the literature. Acta Derm Venereol. 2019;99:508–15.
Fortuna G, Salas-Alanis JC, Guidetti E, Marinkovich MP. A critical reappraisal of the current data on drug-induced linear immunoglobulin A bullous dermatosis: a real and separate nosological entity? J Am Acad Dermatol. 2012;66(6):988–94.
Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, Valeyrie-Allanore L, et al. Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol. 2013;169(5):1041–8.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kardaun, S.H., Meijer, J.M. (2022). Drug-Induced Pemphigoid and Linear IgA Disease. In: Horváth, B. (eds) Autoimmune Bullous Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-91557-5_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-91557-5_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-91556-8
Online ISBN: 978-3-030-91557-5
eBook Packages: MedicineMedicine (R0)